Cutrupi AN, Brewer MH, Nicholson GA, Kennerson ML. Structural variations causing inherited peripheral neuropathies: A paradigm for understanding genomic organization, chromatin interactions, and gene dysregulation. Mol Genet Genomic Med. 2018;6:422--433. <https://doi.org/10.1002/mgg3.390> 29573232

1. INTRODUCTION {#mgg3390-sec-0001}
===============

Inherited peripheral neuropathies (IPNs) are a group of diseases causing length‐dependent axonal degeneration of the peripheral motor and/or sensory nerves resulting in chronic disability. They are among the most common inherited neuromuscular diseases affecting approximately 1 in 2,500 people (Skre, [1974](#mgg3390-bib-0081){ref-type="ref"}). IPNs are classified into one of three subtypes based on the pathology predominantly affecting the motor nerves (hereditary motor neuropathy---HMN), sensory nerves (hereditary sensory and autonomic neuropathy---HSAN) or both motor and sensory nerves (Charcot‐Marie‐Tooth neuropathy---CMT) (Baets & Timmerman, [2011](#mgg3390-bib-0005){ref-type="ref"}). Over 1,000 mutations in more than 80 genes have been associated with IPN subtypes (Timmerman, Strickland, & Zuchner, [2014](#mgg3390-bib-0085){ref-type="ref"}). However, despite these discoveries, numerous whole‐exome sequencing studies to screen IPN cohorts have shown 18%--50% of cases (or higher) remain unsolved creating a significant burden for IPN diagnosis (Drew et al., [2015](#mgg3390-bib-0021){ref-type="ref"}; Hartley et al., [2017](#mgg3390-bib-0031){ref-type="ref"}; Lupo et al., [2016](#mgg3390-bib-0057){ref-type="ref"}; Schabhuttl et al., [2014](#mgg3390-bib-0077){ref-type="ref"}). In these cases where exome sequencing has failed to identify mutations in specific genes, it is likely a proportion of the neuropathy cases may be due to noncoding DNA or structural variation (SV) mutations. We have recently identified novel SV mutations causing two forms of IPN -- X‐Linked Charcot‐Marie‐Tooth neuropathy (CMTX3) (Brewer et al., [2016](#mgg3390-bib-0012){ref-type="ref"}) and distal hereditary motor neuropathy (DHMN1) (Drew, Cutrupi, Brewer, Nicholson, & Kennerson, [2016](#mgg3390-bib-0020){ref-type="ref"}). Our findings have added to the spectrum of mutations causing IPN and highlight the importance of interrogating the noncoding genome for SV mutations for IPN families that have been excluded for genome wide protein coding mutations. We also propose that the CMTX3 and DHMN1 disease causing genomic rearrangements may provide a suitable paradigm for studying the growing area of 3D genomic organization and its underlying role in mechanisms of gene dysregulation.

2. STRUCTURAL VARIATION {#mgg3390-sec-0002}
=======================

Genetic research in IPNs has been pioneering in the discovery of genomic disorders. Perhaps most importantly, it has expanded our understanding of the effects of copy number variation SVs in disease pathogenesis. Advancement in sequencing and genomic technologies including high‐throughput massively parallel sequencing, and array‐based techniques such as array comparative genomic hybridization (aCGH) has led to the development of diverse approaches for SV discovery as well as studying the functional and phenotypic consequences of SV rearrangements (Hoyle, Isfort, Roggenbuck, & Arnold, [2015](#mgg3390-bib-0035){ref-type="ref"}; Hurles, Dermitzakis, & Tyler‐Smith, [2008](#mgg3390-bib-0037){ref-type="ref"}; Weischenfeldt, Symmons, Spitz, & Korbel, [2013](#mgg3390-bib-0090){ref-type="ref"}).

Structural variation is a broad term that encompasses genomic rearrangements that disrupt chromosomal organization and architecture. There are many types of structural variation including duplications and deletions (also referred to as copy number variation \[CNV\]), insertions, inversions, and translocations. These have been reviewed in detail elsewhere (Alkan, Coe, & Eichler, [2011](#mgg3390-bib-0002){ref-type="ref"}; Guan & Sung, [2016](#mgg3390-bib-0029){ref-type="ref"}; Stankiewicz & Lupski, [2010](#mgg3390-bib-0083){ref-type="ref"}). The size of SV DNA rearrangements can range from thousands to millions of base pairs (Gu, Zhang, & Lupski, [2008](#mgg3390-bib-0028){ref-type="ref"}). SV can also be complex. A simple SV event may be part of a more complex rearrangement involving 2 or more types of SV. Such examples include translocation insertions (Antonarakis, Kazazian, & Tuddenham, [1995](#mgg3390-bib-0003){ref-type="ref"}; Brewer et al., [2016](#mgg3390-bib-0012){ref-type="ref"}), translocation deletions (Barber, Ford, Harris, Harrison, & Moorman, [2004](#mgg3390-bib-0007){ref-type="ref"}), and inversion duplications (Kostiner, Nguyen, Cox, & Cotter, [2002](#mgg3390-bib-0050){ref-type="ref"}). The scale and complexity of SV can therefore cause major re‐organization of the regulatory landscape of genomic loci. It accounts for a considerable proportion of genetic variability, phenotypic diversity, and human disease (Feuk, Carson, & Scherer, [2006](#mgg3390-bib-0024){ref-type="ref"}; Guan & Sung, [2016](#mgg3390-bib-0029){ref-type="ref"}; Redon et al., [2006](#mgg3390-bib-0073){ref-type="ref"}; Weischenfeldt et al., [2013](#mgg3390-bib-0090){ref-type="ref"}) with SVs having more heritable differences between individuals than SNPs (Baker, [2012](#mgg3390-bib-0006){ref-type="ref"}; Weischenfeldt et al., [2013](#mgg3390-bib-0090){ref-type="ref"}). Reference to structural variation in both the scientific literature and in curated databases such as the Database of Genomic Variants (DGV‐ <http://dgv.tcag.ca/dgv/app/home>) has grown significantly (Baker, [2012](#mgg3390-bib-0006){ref-type="ref"}; J. R. Lupski et al., [1991](#mgg3390-bib-0058){ref-type="ref"}). SV represents an excellent candidate for disease causing mutations for IPN, especially when genome wide protein coding point mutations have been excluded in unsolved families.

2.1. Known structural variation causing IPN {#mgg3390-sec-0003}
-------------------------------------------

The most common IPN subtype, CMT1A is caused by a 1.5‐Mb tandem duplication of chromosome 17p11.2 (Lupski et al., [1991](#mgg3390-bib-0058){ref-type="ref"}) which results in trisomy of the gene encoding peripheral myelin protein 22 (*PMP22,* OMIM:\*106907) (Lupski et al., [1992](#mgg3390-bib-0059){ref-type="ref"}; Patel et al., [1992](#mgg3390-bib-0069){ref-type="ref"}; Timmerman et al., [1992](#mgg3390-bib-0084){ref-type="ref"}; Valentijn et al., [1992](#mgg3390-bib-0089){ref-type="ref"}). The CMT1A duplication represents the first and most common IPN mutation (Inoue et al., [2001](#mgg3390-bib-0040){ref-type="ref"}), accounting for approximately 50% of all CMT cases (Katona et al., [2009](#mgg3390-bib-0046){ref-type="ref"}). Reciprocal deletion of the same chromosome 17p11.2 region causes hereditary neuropathy with liability to pressure palsies (HNPP) which results in a mild, episodic peripheral neuropathy (Chance et al., [1993](#mgg3390-bib-0015){ref-type="ref"}). At the time of reporting the CMT1A duplication/HNPP deletion, this represented a seminal discovery for structural variation (CNV) causing IPN and demonstrated the sensitivity of nervous tissue to gene dosage changes due to the gain or loss of a copy of the *PMP22* gene.

Atypical genomic rearrangements have also been identified for the CMT1A/HNPP locus and other IPN loci (Table [1](#mgg3390-tbl-0001){ref-type="table"}). For CMT1A these include duplications that differ in size to the 1.5 Mb genomic rearrangement (Valentijn et al., [1993](#mgg3390-bib-0088){ref-type="ref"}) and small exonic deletions involving all or part of *PMP22* gene coding exons (Zhang et al., [2010](#mgg3390-bib-0092){ref-type="ref"}). Two novel duplications that exclude the *PMP22* coding region have also been identified in cases of CMT1A (Weterman et al., [2010](#mgg3390-bib-0091){ref-type="ref"}; Zhang et al., [2010](#mgg3390-bib-0092){ref-type="ref"}). Weterman et al., reported a 186 kb duplication located upstream of the *PMP22* gene in six unrelated families (Weterman et al., [2010](#mgg3390-bib-0091){ref-type="ref"}). Work by Zhang et al., examined the contribution of nonrecurrent genomic rearrangements to CMT1A/HNPP and confirmed the previously reported 186 kb duplication in 2 of 21 subjects. The study also identified a novel 194 kb duplication upstream of the *PMP22* gene in one patient (Zhang et al., [2010](#mgg3390-bib-0092){ref-type="ref"}). Both the 186 kb and 194 kb duplication mutations shared a common overlapping region of approximately 168 kb (Zhang et al., [2010](#mgg3390-bib-0092){ref-type="ref"}). This region has since been shown to contain several putative enhancers of the *PMP22* gene (Jones et al., [2011](#mgg3390-bib-0044){ref-type="ref"}, [2012](#mgg3390-bib-0043){ref-type="ref"}) which when duplicated cause CMT1A. Cases describing whole or partial gene duplications or deletions at other CMT loci include *MPZ* (OMIM:\*159440) (Hoyer, Braathen, Eek, Skjelbred, & Russell, [2011](#mgg3390-bib-0034){ref-type="ref"}; Maeda et al., [2012](#mgg3390-bib-0060){ref-type="ref"}), *MFN2* (OMIM:\*608507) (Carr et al., [2015](#mgg3390-bib-0014){ref-type="ref"}), *GJB1* (OMIM:\*304040) (Ainsworth, Bolton, Murphy, Stuart, & Hahn, [1998](#mgg3390-bib-0001){ref-type="ref"}; Lin et al., [1999](#mgg3390-bib-0055){ref-type="ref"}; Nakagawa et al., [2001](#mgg3390-bib-0064){ref-type="ref"}), and *NDRG1* (OMIM:\*605262) (Okamoto et al., [2014](#mgg3390-bib-0067){ref-type="ref"}). Apart from these reports, however, CNV disrupting other IPN loci appear to be rare. Three independent studies used aCGH to examine the contribution of CNV to IPN and all concluded that apart from the CMT1A duplication/HNPP deletion, CNV as a disease mechanism in IPN is rare (Hoyer et al., [2015](#mgg3390-bib-0033){ref-type="ref"}; Huang et al., [2010](#mgg3390-bib-0036){ref-type="ref"}; Pehlivan et al., [2016](#mgg3390-bib-0070){ref-type="ref"}).

###### 

Structural variations reported for IPN loci

  References                                                      Phenotype   Description                                    Approximate Size (kb)   Mechanism                                  HGVS/ISCN (GRCh38/hg38)
  --------------------------------------------------------------- ----------- ---------------------------------------------- ----------------------- ------------------------------------------ -----------------------------------------------------------------------------------------------
  Lupski et al., ([1991](#mgg3390-bib-0058){ref-type="ref"})      CMT1A       Duplication involving *PMP22*                  1,500                   Gene dosage of *PMP22*                     Chr17:g.(14170534_14194724)\_(15567585‐15591587)dup
  Valentijn et al., ([1993](#mgg3390-bib-0088){ref-type="ref"})   CMT1A       Duplication involving *PMP22*                  450                     Gene dosage of *PMP22*                     Undetermined
  Zhang et al., ([2010](#mgg3390-bib-0092){ref-type="ref"})       CMT1A       Duplication of sequences upstream of *PMP22*   194                     Dysregulation of *PMP22* gene expression   Chr17:g.(15467580_15467581)ins(15274153_15467575)
  Weterman et al., ([2010](#mgg3390-bib-0091){ref-type="ref"})    CMT1A       Duplication of sequences upstream of *PMP22*   186                     Dysregulation of *PMP22* gene expression   Chr17:g.(15485748_15485749)ins(15299622‐15485747)
  Zhang et al., ([2010](#mgg3390-bib-0092){ref-type="ref"})       CMT1A       Duplication involving *PMP22*                  412                     Gene dosage of *PMP22*                     Chr17:g.(15624595_15624596)ins(15213043‐15624585)
  Zhang et al., ([2010](#mgg3390-bib-0092){ref-type="ref"})       CMT1A       Deletion involving *PMP22*                     536                     Gene dosage of *PMP22*                     Chr17:g.14709310_15245549del
  Zhang et al., ([2010](#mgg3390-bib-0092){ref-type="ref"})       CMT1A       Complex rearrangement involving *PMP22*        3,400                   Gene dosage of *PMP22*                     Undetermined
  Zhang et al., ([2010](#mgg3390-bib-0092){ref-type="ref"})       CMT1A       Complex rearrangement involving *PMP22*        1,294                   Gene dosage of *PMP22*                     Undetermined
  Chance et al., ([1993](#mgg3390-bib-0015){ref-type="ref"})      HNPP        Deletion involving *PMP22*                     24                      Gene dosage of *PMP22*                     Chr17:g.(14170534_14194724)\_(15567585_15591587)del
  Nadal et al., ([2000](#mgg3390-bib-0063){ref-type="ref"})       HNPP        Translocation                                  Undetermined            Dysregulation of gene expression           t(16;17)(q12;p11.2)
  Ainsworth et al., ([1998](#mgg3390-bib-0001){ref-type="ref"})   CMTX1       Deletion involving *GJB1*                      Undetermined            Gene dosage of *GJB1*                      Undetermined
  Rouger et al., ([1997](#mgg3390-bib-0075){ref-type="ref"})      CMTX1       Complex rearrangement involving *GJB1*         Undetermined            Undetermined                               Undetermined
  Maeda et al., ([2012](#mgg3390-bib-0060){ref-type="ref"})       CMT1B       Duplication involving *MPZ*                    117                     Gene Dosage of *MPZ*                       Chr1:g.(161415803_161415804)ins(161298102_161415774)
  Brewer et al., ([2016](#mgg3390-bib-0012){ref-type="ref"})      CMTX3       Complex Insertion                              78                      Dysregulation of gene expression           ChrX:g.140420783_140420784ins\[chr8:g.144542928_144620773;TTCCTTCCT\]g.138490706_138490718inv
  Drew et al., ([2016](#mgg3390-bib-0020){ref-type="ref"})        DHMN1       Complex Insertion                              1,350                   Dysregulation of gene expression           Chr7:153636339_153637495delins\[GGTGCGGGCTCCT;g.155856471_157199742inv; AGTATGGCTGTAAGTGACGTC
  Zhang et al., ([2010](#mgg3390-bib-0092){ref-type="ref"})       CMT1A       Deletion                                       17                      Gene dosage of *PMP22*                     Chr17:g.15234989_15252302delins\[CAT\]
  Lin et al., ([1999](#mgg3390-bib-0055){ref-type="ref"})         CMTX1       Deletion involving *GJB1*                      1.5                     Gene dosage of *GJB1*                      ChrX:g.71306403_71307859del
  Nakagawa et al., ([2001](#mgg3390-bib-0064){ref-type="ref"})    CMTX1       Deletion involving *GJB1*                      1.5                     Gene dosage of *GJB1*                      ChrX:g.71306977_71307427del
  Hoyer et al., ([2011](#mgg3390-bib-0034){ref-type="ref"})       CMT1B       Duplication involving *MPZ*                    4                       Gene Dosage of *MPZ*                       Chr1:g.161304727_161308898dup
  Okamoto et al., ([2014](#mgg3390-bib-0067){ref-type="ref"})     CMT4D       Exonic Duplication involving *NDRG1*           6.25                    Gene Dosage of *NDRG1*                     Chr8:g.133252822_133259076dup
  Carr et al., ([2015](#mgg3390-bib-0014){ref-type="ref"})        CMT2A       Exonic Deletion involving *MFN2*               Undetermined            Gene Dosage of *MFN2*                      Undetermined

Undetermined = insufficient information provided in published data.
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Complex structural variations have been described that disrupt known IPN loci and include rearrangements for CMTX1 involving the entire coding region (Rouger et al., [1997](#mgg3390-bib-0075){ref-type="ref"}), as well as a reciprocal translocation t(16;17)(q12;p11.2) causing HNPP (Nadal et al., [2000](#mgg3390-bib-0063){ref-type="ref"}). The involvement and contribution of non‐CNV structural variations as a pathomechanism in IPN therefore remains largely understudied and poorly understood.

2.2. Discovery of two complex insertions expands the mutation spectrum of IPN {#mgg3390-sec-0004}
-----------------------------------------------------------------------------

Our laboratory has recently identified two novel SVs as the underlying genetic causes of an X‐linked form of CMT (CMTX3, OMIM:%302802) (Brewer et al., [2016](#mgg3390-bib-0012){ref-type="ref"}); and an autosomal dominant form of distal HMN (DHMN1, OMIM:%182960) (Drew et al., [2016](#mgg3390-bib-0020){ref-type="ref"}). Linkage analyses in large families mapped the respective disease loci to chromosome Xq26.3‐q27.3 for CMTX3 (Huttner, Kennerson, Reddel, Radovanovic, & Nicholson, [2006](#mgg3390-bib-0038){ref-type="ref"}) and chromosome 7q34‐q36.2 for DHMN1 (Gopinath, Blair, Kennerson, Jennifer, & Nicholson, [2007](#mgg3390-bib-0027){ref-type="ref"}). Following identification of the respective disease loci, whole‐exome sequencing, CNV, and karyotype analyses failed to identify any candidate gene mutations for CMTX3 and DHMN1. Paired end whole‐genome sequencing (WGS) was then performed on multiple affected individuals from the CMTX3 and DHMN1 families and analyzed for split and discordant map reads. The analysis revealed a large complex insertion within the respective CMTX3 and DHMN1 disease locus. CMTX3 patients had a 78 kb duplication of chromosome 8q24.3 inserted into the CMTX3 locus at chromosome Xq27.1 (Figure [1](#mgg3390-fig-0001){ref-type="fig"}). For DHMN1 patients, a 1.35 Mb duplication of chromosome 7q36.3 was inserted into the DHMN1 locus at chromosome 7q36.2 in the reverse orientation (Figure [2](#mgg3390-fig-0002){ref-type="fig"}). Both SVs segregated with the disease in their respective families. The SVs were absent in the unaffected individuals sent for WGS, 1054 neurologically normal control chromosomes, and the DGV database.

![The CMTX3 complex insertion. Ideogram of chromosome 8 and chromosome X expanded to show (a) the region of chromosome 8q24.3 inserted into (b) the CMTX3 locus on chromosome X. Purple areas represent sequence contained within the CMTX3 locus. Orange areas represent the region of chromosome 8q23.4 inserted into the CMTX3 locus. Breakpoints are indicated by the vertical black broken lines. Letters A--D indicate sequences flanking the breakpoints. (c) Relative positions of the genes contained within the complex insertion and flanking the insertion site within the CMTX3 locus. Adapted from the gene track of UCSC Genome Browser (GRCh38/hg38) for the different genomic interval on chromosome Xq27.1 and chromosome 8q24.3](MGG3-6-422-g001){#mgg3390-fig-0001}

![The DHMN1 complex insertion. Ideogram of chromosome 7 expanded to show (a) the normal and (b) DHMNI locus. Blue areas represent sequence within the DHMN1 locus. Orange areas represent sequence at chromosome 7q36.3 inserted into the DHMN1 locus. The chromosome 7q36.3 sequence is located 2.3 Mb distal to the DHMN1 locus. Breakpoints are indicated by the vertical black broken lines. Letters A--G indicate sequences flanking the breakpoints. The sequence FG from chromosome 7q36.3 has been inserted into the DHMN1 locus in inverted orientation. (c) Relative positions of the genes contained within the complex insertion and flanking the insertion site within the DHMN1 locus. Adapted from gene tracks of the UCSC Genome Browser (GRCh38/hg38) for the specific chromosome 7q36.3 and 7q36.2 genomic intervals](MGG3-6-422-g002){#mgg3390-fig-0002}

Our two SV discoveries expand the spectrum of mutations known to cause IPN (Figure [3](#mgg3390-fig-0003){ref-type="fig"}) and raise some significant questions with respect to the biological impact of SV mutations in peripheral nerve and their role in gene dysregulation as a disease mechanism for IPN.

![Structural Variation expands the mutation spectrum of IPN. Classes of genetic mutations and the size of the DNA re‐arrangements caused by structural variation. The two large complex insertions for CMTX3 and DHMN1 neuropathy highlight the growing role of structural variation in the pathogenicity of IPN](MGG3-6-422-g003){#mgg3390-fig-0003}

3. PATHOGENIC MECHANISMS OF SV MUTATIONS {#mgg3390-sec-0005}
========================================

Insights into the mechanisms that underpin the relationship between SV and disease pathogenesis have been garnered from studies on a range of diseases including Hemophillia A (reviewed in (Tuddenham et al., [1991](#mgg3390-bib-0087){ref-type="ref"})), Parkinson\'s Disease (Marongiu et al., [2007](#mgg3390-bib-0061){ref-type="ref"}; Singleton et al., [2003](#mgg3390-bib-0080){ref-type="ref"}), and Aniridia (Fantes et al., [1995](#mgg3390-bib-0023){ref-type="ref"}; Fukushima et al., [1993](#mgg3390-bib-0025){ref-type="ref"}; Simola, Knuutila, Kaitila, Pirkola, & Pohja, [1983](#mgg3390-bib-0079){ref-type="ref"}). These studies have revealed that SVs can cause disease by several mechanisms including (i) physical disruption of the DNA structure of genes, (ii) the unmasking of recessive alleles or functional polymorphisms, (iii) alteration of gene dosage of dosage sensitive genes via copy number change, and (iv) disrupting/altering the spatiotemporal control of gene expression causing gene dysregulation/ectopic expression (Kleinjan & Lettice, [2008](#mgg3390-bib-0048){ref-type="ref"}; Kleinjan & Van Heyningen, [2005](#mgg3390-bib-0049){ref-type="ref"}; Spielmann & Mundlos, [2013](#mgg3390-bib-0082){ref-type="ref"}). Given that the CMTX3 and DHMN1 SVs are complex insertions, we propose two possible mechanisms that could lead to the different neuropathy in our families: (i) altered gene dosage resulting from trisomy of the complex inserted regions; or (ii) transcriptional dysregulation of one or more genes mapping within the CMTX3 and DHMN1 disease loci and flanking regions.

The 78 kb CMTX3 duplication of chromosome 8q24.3 contains a partial transcript (exons 1--7) of the *ARHGAP39* (OMIM:\*615880) gene which is encoded on the negative strand. The duplicated chromosome 8q24.3 sequence is inserted into an intergenic region of chromosome Xq27.1 with *LOC389895* and *SOX3* (OMIM:\*313430) being the nearest flanking genes (Brewer et al., [2016](#mgg3390-bib-0012){ref-type="ref"}) (Figure [1](#mgg3390-fig-0001){ref-type="fig"}). The 1.35 Mb DHMN1 SV duplication of chromosome 7q36.3 involves five protein‐coding genes (*LOC389602*,*RNF32* (OMIM:\*610241), *LMBR* (OMIM:\*605522), *NOM1* (OMIM:\*611269), *MNX1* (OMIM:\*142994)), a partial transcript of the *UBE3C* (OMIM:\*614454) gene (exons 1--9), three long noncoding RNAs (lncRNA; *LOC285889*,*LINC01006*,*MNX1*‐*AS1)* and several putative enhancers and promoters. The location of the insertion occurs within a gene desert of the DHMN1 locus between the proximal *ACTR3B* gene and the distal *DPP6* (OMIM:\*126141) gene. The closest genomic element is a lncRNA *LINC01287* transcribed on the negative strand (Drew et al., [2016](#mgg3390-bib-0020){ref-type="ref"}) (Figure [2](#mgg3390-fig-0002){ref-type="fig"}).

3.1. Gene dosage {#mgg3390-sec-0006}
----------------

The CMT1A/HNPP duplication/deletion sets a precedent for a SV disease mechanism in IPN causing peripheral nerves to be sensitive to gene dosage changes. For both CMTX3 and DHMN1, trisomy of any gene transcripts (whole or partial) within the inserted DNA may result in gene dosage effects and produce neuropathy. For CMTX3, differential expression of *ARHGAP39* in lymphoblasts using qPCR was not observed between patients and controls suggesting that trisomy of the partial transcript was not likely to be the mechanism underlying CMTX3 pathology (Brewer et al., [2016](#mgg3390-bib-0012){ref-type="ref"}). When testing genes for DHMN1, the expression of the partial transcript *UBE3C* was higher in patients when compared to controls which may suggest a gene dosage mechanism for DHMN1 (unpublished data). Interestingly, the inserted sequence from chromosome 7q36.3 contains the fully intact *MNX1/HB9* gene along with associated promoter and flanking sequences. *MNX1/HB9* encodes a motor neuron transcription factor which is crucial for the consolidation of motor neuron identity (Arber et al., [1999](#mgg3390-bib-0004){ref-type="ref"}). Models of ALS (Peviani et al., [2012](#mgg3390-bib-0071){ref-type="ref"}) and CMT2A (Detmer, Vande Velde, Cleveland, & Chan, [2008](#mgg3390-bib-0018){ref-type="ref"}) have used the *MNX1/HB9* gene promoter to express genes of interest in mouse motor neurons. Although a gene dosage effect cannot currently be ruled out for DHMN1, these studies suggest that it is highly plausible that the *MNX1/HB9* promoter or flanking regulatory sequences could be driving expression of nearby genes in DHMN1 motor neurons. To address this question and the relevance of gene expression changes in peripheral nerve of DHMN1 patients these findings will need to be reproduced in patient‐derived neural tissue.

3.2. Disruption to transcriptional regulation {#mgg3390-sec-0007}
---------------------------------------------

Gene dysregulation through aberrant transcriptional regulation is not unprecedented as a disease mechanism in IPN as point mutations have previously been reported in noncoding regulatory sequences (Tomaselli et al., [2017](#mgg3390-bib-0086){ref-type="ref"}). Point mutations in the 5′ untranslated region (UTR), 3′ UTR (Ionasescu, Searby, Ionasescu, Neuhaus, & Werner, [1996](#mgg3390-bib-0041){ref-type="ref"}) and the neural‐specific promoter (P2) sequences of the *GJB1* gene (Houlden et al., [2004](#mgg3390-bib-0032){ref-type="ref"}) have been reported to cause CMTX1. Similarly, point mutations in the 5′ UTR of the *SEPT9* (OMIM:\*604061) gene cause hereditary neuralgic amyotrophy (HNA) (Kuhlenbaumer et al., [2005](#mgg3390-bib-0052){ref-type="ref"}). These mutations highlight the importance of noncoding sequence mutations in IPN as well as the broader context of human disease.

Structural variations like those causing CMTX3 and DHMN1 may disrupt transcriptional regulation of one or more gene(s) by altering the cis‐acting regulatory element environments. The cis‐acting regulatory environment contains a number of different sequences or "regulatory elements" that bind *trans‐*acting regulatory proteins (transcription factor binding proteins‐TFBPs) and modulate the activity of genes and other transcribed regions of the genome at distances of up to 2--3 Mb. Large genomic rearrangements have been shown to disrupt noncoding, regulatory DNA sequences that structurally alter the regulatory environment. Significant changes in the activity of one or more genes resulting in disease can occur by disrupting the interaction between a gene(s) and regulatory sequences (such as promoters, enhancers/repressors) or introducing new or altered chromatin interactions (Dixon et al., [2012](#mgg3390-bib-0019){ref-type="ref"}; Lupianez et al., [2015](#mgg3390-bib-0056){ref-type="ref"}; Spielmann & Mundlos, [2013](#mgg3390-bib-0082){ref-type="ref"}).

Quantitative gene expression analysis showed that the CMTX3 candidate gene *FGF13* (OMIM:\*300070) had increased expression in patient lymphoblasts compared to controls and confirmed the complex insertion of chromosome 8q24.3 sequence into chromosome Xq27.1 can dysregulate genes in the CMTX3 linkage region. Further gene expression studies in disease‐relevant tissues for candidate genes mapping to the CMTX3 and DHMN1 loci are therefore necessary to fully elucidate the pathogenic consequences of the CMTX3 and DHMN1 complex insertions.

Interestingly, several other phenotypes in addition to CMTX3 have been reported in which different large chromosomal sequences have been inserted into the same region of chromosome Xq27.1. These include ptosis (Bunyan et al., [2014](#mgg3390-bib-0013){ref-type="ref"}), hyperthyroidism (Bowl et al., [2005](#mgg3390-bib-0011){ref-type="ref"}), hypertrichosis (De Stefano et al., [2013](#mgg3390-bib-0017){ref-type="ref"}; Zhu et al., [2011](#mgg3390-bib-0093){ref-type="ref"}), and XX male sex reversal (Haines et al., [2015](#mgg3390-bib-0030){ref-type="ref"}). Although a precise disease mechanism is yet to be elucidated, the multiple phenotypes observed due to insertions at chromosome Xq27.1 raises two possibilities: (i) juxtaposition of a candidate gene with a regulatory element that would otherwise not normally regulate that gene; (ii) the inserted sequence could contain gene regulatory elements which, placed in proximity to genes in the CMTX3 linkage region may result in ectopic neural specific expression.

3.3. Altered chromatin environment {#mgg3390-sec-0008}
----------------------------------

Another important consideration for pathogenic mechanisms underlying the CMTX3 and DHMN1 SV mutations is the effect of structural changes at the chromatin level of organization. Changes in the chromatin structure at a given locus can mediate the interaction between genes and their associated regulatory sequences (Kleinjan & Lettice, [2008](#mgg3390-bib-0048){ref-type="ref"}; Schluth‐Bolard, Ottaviani, Gilson, & Magdiner, [2011](#mgg3390-bib-0078){ref-type="ref"}). It is becoming increasingly recognized that these interactions take place within the context of a "3D genome" in which multiple, complex genome interactions, and configurations determine important biological functions such as DNA replication, DNA repair, and transcription (Bonev & Cavalli, [2016](#mgg3390-bib-0009){ref-type="ref"}). Chromosome conformation capture studies examining the frequency of chromatin interactions have demonstrated that functions of the genome such as control of gene expression are moderated by chromosomes being linearly partitioned into topologically associated domains (TADs) (Bonev & Cavalli, [2016](#mgg3390-bib-0009){ref-type="ref"}; Dixon et al., [2012](#mgg3390-bib-0019){ref-type="ref"}; Krijger & De Laat, [2016](#mgg3390-bib-0051){ref-type="ref"}; Olivares‐Chauvet et al., [2016](#mgg3390-bib-0068){ref-type="ref"}). TADs are regions that demarcate chromosomal microenvironments in which sequences far apart in the genome preferentially come in close proximity to make contact with each other (Bouwman & De Laat, [2015](#mgg3390-bib-0010){ref-type="ref"}). The contact between these linearly disparate sequences occurs through the 3D conformation of the genome. Little is known about the extent to which pathogenic SVs are known to alter the spatial organization of the genome causing disease. However, work in developmental and congenital disorders and cancer have provided some useful insights into the potential mechanisms that underpin the gene dysregulation resulting from altered spatial organization of the genome. These include (i) disruption to TAD boundaries, resulting in aberrant enhancer‐promoter interactions; (ii) altering the contents of TADs, thereby introducing novel interactions (reviewed in (Kaiser & Semple, [2017](#mgg3390-bib-0045){ref-type="ref"})). Interestingly, studies have shown that the architecture of TADs remains relatively conserved at the megabase scale between tissue types (Berlivet et al., [2013](#mgg3390-bib-0008){ref-type="ref"}; Dixon et al., [2012](#mgg3390-bib-0019){ref-type="ref"}). However, at the sub‐megabase scale there is evidence suggesting that "sub‐TADs" (Phillips‐Cremins et al., [2013](#mgg3390-bib-0072){ref-type="ref"}) can vary among different tissues (Berlivet et al., [2013](#mgg3390-bib-0008){ref-type="ref"}; Phillips‐Cremins et al., [2013](#mgg3390-bib-0072){ref-type="ref"}), particularly for differentially expressed genes (Dixon et al., [2012](#mgg3390-bib-0019){ref-type="ref"}). Therefore, it is plausible that CMTX3 and DHMN1 could represent 'TADopathies' (Matharu & Ahituv, [2015](#mgg3390-bib-0062){ref-type="ref"}) in which the disruption of sub‐megabase scale interactions within peripheral nerve sub‐TADs could produce neuropathy. The CMTX3 and DHMN1 genomic rearrangements, therefore represent an ideal naturally occurring paradigm to study the disruption of chromatin organization and the impact on gene regulation.

4. CHALLENGES AND FUTURE STRATEGIES TO STUDY SV CAUSING IPNS {#mgg3390-sec-0009}
============================================================

Unlike protein coding mutations, SV mutations such as those causing CMTX3 and DHMN1 may not immediately reveal a causative gene. This raises some important considerations and challenges within this exciting area of IPN research.

Large SVs causing pathogenic genomic rearrangements will increase the number of candidate genes to consider as causative. In some diseases, multiple genes disrupted by SV events may contribute to disease pathology (reviewed in (Iyer & Girirajan, [2015](#mgg3390-bib-0042){ref-type="ref"})). For CMT1A/HNPP, the 1.5 Mb region which encompasses 8 gene transcripts and several noncoding RNAs is specifically caused by trisomy of the *PMP22* gene. Given that CMTX3 and DHMN1 are Mendelian diseases, it is likely that the neuropathy will be caused by mutations affecting a single gene. In the event that multiple genes are dysregulated, identifying point mutations in these candidate genes that segregate in unsolved families could provide further evidence for the gene being causative. This was the case for CMT1A and HNPP where point mutations in the *PMP22* gene were identified in families lacking the 1.5 Mb duplication/deletion (Nicholson et al., [1994](#mgg3390-bib-0065){ref-type="ref"}; Roa et al., [1993](#mgg3390-bib-0074){ref-type="ref"}).

To assess the effects of SV mutations, appropriate models are required. Modelling large genomic rearrangements like the CMTX3 and DHMN1 complex insertions are difficult as they exceed the size limit and cloning accuracy of current technologies. In addition, obtaining disease relevant tissue is not possible prior to postmortem. Many studies for IPN have examined gene expression in alternative tissues such as lymphoblast (Zimon et al., [2012](#mgg3390-bib-0094){ref-type="ref"}) and fibroblast cells (Echaniz‐Laguna et al., [2013](#mgg3390-bib-0022){ref-type="ref"}; Kennerson et al., [2010](#mgg3390-bib-0047){ref-type="ref"}). For CMTX3 and DHMN1, observable differences in the expression of *FGF13* and *UBE3C* have been identified in lymphoblasts. However, given that the regulation of gene transcription is likely to occur in a neural tissue specific manner it is not yet clear whether these observed differences are relevant to the CMTX3 and DHMN1 phenotype. To address examining gene expression in neural tissue, motor neurons derived from patient‐induced pluripotent stem cells (iPSCs) are now being used. Several studies have used iPSC‐derived motor neurons (iPSC‐MNs) to model neuromuscular diseases including ALS (Chen et al., [2014](#mgg3390-bib-0016){ref-type="ref"}; Ichiyanagi et al., [2016](#mgg3390-bib-0039){ref-type="ref"}; S. Lee & Huang, [2017](#mgg3390-bib-0053){ref-type="ref"}), SMA (Fuller et al., [2015](#mgg3390-bib-0026){ref-type="ref"}; Nizzardo et al., [2015](#mgg3390-bib-0066){ref-type="ref"}) and various IPNs (G. Lee et al., [2009](#mgg3390-bib-0054){ref-type="ref"}; Saporta et al., [2015](#mgg3390-bib-0076){ref-type="ref"}). iPSCs‐MNs have the potential to model neural specific phenotypic changes, gene expression, and chromatin interactions in disease relevant tissue. This will help to elucidate the disease pathology and identify biological pathways to target for the development of appropriate therapies.

5. CONCLUSION {#mgg3390-sec-0010}
=============

Inherited peripheral neuropathies and other Mendelian diseases have benefited from WES to interrogate protein coding regions of the genome. However, despite the advances in gene discovery and diagnostic testing many cases still remain unsolved. With WGS becoming more cost‐effective, and the improvements in technologies to generate longer sequencing reads, looking beyond the exome for SV mutations is feasible and an important consideration for unsolved cases of IPN and other Mendelian diseases. The current active research to understand the role of genomic interactions in gene regulation will be facilitated by the use of patient derived neural tissue from CMTX3 and DHMN1 patients through iPSC technologies. This review highlights the contribution of SV mutations and gene dysregulation as an important development in understanding the pathogenesis of IPNs.
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